Cellular Biomedicine Group Stock Forecast for 2022 - 2025 - 2030

Updated on 09/27/2022

Stock Rating
2
Price Target
$0.00
Consensus
-
Upside
0.00%
Analysts
0
Stock Rating
2
Upside
0.00%
Analysts
0
Price Target
$0.00
-

Cellular Biomedicine Group Fair Value Forecast for 2022 - 2025 - 2030

Cellular Biomedicine Group's Price has increased by 100.00% In the last year, going from $0.00 to $0.00. In the next year, analysts expect Fair Value to reach $0.00 – an increase of 100.00%. For the next eleven years, the forecast is for Fair Value to grow by 100.00%.

2020 Fair Value Forecast
$0.00
2021 Fair Value Forecast
$0.00
2022 Fair Value Forecast
$0.00
2023 Fair Value Forecast
$0.00
2024 Fair Value Forecast
$0.00
2025 Fair Value Forecast
$0.00
2026 Fair Value Forecast
$0.00
2027 Fair Value Forecast
$0.00
2028 Fair Value Forecast
$0.00
2029 Fair Value Forecast
$0.00
2030 Fair Value Forecast
$0.00

Cellular Biomedicine Group Revenue Forecast for 2022 - 2025 - 2030

Cellular Biomedicine Group's Revenue has increased by 54.55% In the last year, going from $220.00k to $340.00k. In the next year, analysts expect Revenue to reach $459.99k – an increase of 35.29%. For the next eleven years, the forecast is for Revenue to grow by 710.68%.

2020 Rev Forecast
$459.99k
2021 Rev Forecast
$594.07k
2022 Rev Forecast
$760.29k
2023 Rev Forecast
$938.99k
2024 Rev Forecast
$0.00B
2025 Rev Forecast
$0.00B
2026 Rev Forecast
$0.00B
2027 Rev Forecast
$0.00B
2028 Rev Forecast
$0.00B
2029 Rev Forecast
$0.00B
2030 Rev Forecast
$0.00B

Cellular Biomedicine Group Dividend per Share Forecast for 2022 - 2025 - 2030

Cellular Biomedicine Group Free Cash Flow Forecast for 2022 - 2025 - 2030

In the last year, Cellular Biomedicine Group's Free Cash Flow has grown from $-31.70M to $-50.32M – a 58.74% increase. In the following year, the 0 analysts surveyed believe that Cellular Biomedicine Group's Free Cash Flow will decrease by 37.00%, reaching $-31.70M. According to professionals, by 2030, Cellular Biomedicine Group's Free Cash Flow will have decreased by 18.43%, falling down to $-41.05M.

2020 FCF Forecast
$-31701600.00
2021 FCF Forecast
$-40203969.12
2022 FCF Forecast
$-40281696.79
2023 FCF Forecast
$-45302138.94
2024 FCF Forecast
$-40406487.79
2025 FCF Forecast
$-40520972.84
2026 FCF Forecast
$-40623625.97
2027 FCF Forecast
$-42193052.05
2028 FCF Forecast
$-41595317.15
2029 FCF Forecast
$-41244529.97
2030 FCF Forecast
$-41047931.05

Cellular Biomedicine Group Net Income Forecast for 2022 - 2025 - 2030

In the last year, Cellular Biomedicine Group's Net Income has grown by 28.32%, from $-38.95M to $-49.98M. For the following year, the 0 analysts predict that Cellular Biomedicine Group's Net Income will drop by 22.07%, reaching $-38.95M. In 2030, the professionals' prediction is that CBMG's Net Income will decrease by 12.87%, reaching $-43.55M.

2020 NI Forecast
$-38949414.00
2021 NI Forecast
$-43437684.81
2022 NI Forecast
$-42846932.29
2023 NI Forecast
$-45613415.89
2024 NI Forecast
$-43329704.20
2025 NI Forecast
$-43413474.96
2026 NI Forecast
$-43270210.49
2027 NI Forecast
$-44050516.62
2028 NI Forecast
$-43811175.48
2029 NI Forecast
$-43681202.33
2030 NI Forecast
$-43547246.64

Cellular Biomedicine Group EBITDA Forecast for 2022 - 2025 - 2030

In the last year, Cellular Biomedicine Group's EBITDA has grown by 39.37%, rising from $-32.54M to $-45.35M. The next year, 0 experts forecast that Cellular Biomedicine Group's EBITDA will decrease by 28.25%, reaching $-32.54M. In 2030, professionals predict that Cellular Biomedicine Group's EBITDA will decrease by 15.58%, reaching $-38.29M.

2020 EBITDA Forecast
$-32538625.00
2021 EBITDA Forecast
$-38014875.59
2022 EBITDA Forecast
$-37597979.12
2023 EBITDA Forecast
$-40865243.50
2024 EBITDA Forecast
$-37963811.22
2025 EBITDA Forecast
$-38058720.74
2026 EBITDA Forecast
$-37981334.68
2027 EBITDA Forecast
$-38942262.45
2028 EBITDA Forecast
$-38615147.44
2029 EBITDA Forecast
$-38432369.08
2030 EBITDA Forecast
$-38286326.07

Cellular Biomedicine Group EBIT Forecast for 2022 - 2025 - 2030

In the last year, Cellular Biomedicine Group's EBIT has grown by 35.65%, rising from $-37.59M to $-50.99M. According to the 0 analysts polled, in the next year, Cellular Biomedicine Group's EBIT will fall by 26.28%, reaching $-37.59M. By 2030, professionals believe that Cellular Biomedicine Group's EBIT will have decreased by 14.76%, falling to $-43.46M.

2020 EBIT Forecast
$-37589828.00
2021 EBIT Forecast
$-43230808.19
2022 EBIT Forecast
$-42700510.27
2023 EBIT Forecast
$-46093777.49
2024 EBIT Forecast
$-43148385.11
2025 EBIT Forecast
$-43250502.95
2026 EBIT Forecast
$-43139493.33
2027 EBIT Forecast
$-44124511.76
2028 EBIT Forecast
$-43799461.19
2029 EBIT Forecast
$-43619883.40
2030 EBIT Forecast
$-43462851.82

Cellular Biomedicine Group EPS Price Prediction Forecast for 2022 - 2025 - 2030

Cellular Biomedicine Group's EPS has increased by 49.43% In the last year, going from $-1.76 to $-2.63. In the following year, 0 experts forecast that Cellular Biomedicine Group's EPS will decrease by 33.08%, to $-1.76. In 2030, professionals predict that Cellular Biomedicine Group's EPS will decrease by 17.31%, to $-2.17.

2020 EPS Forecast
$-1.76
2021 EPS Forecast
$-2.15
2022 EPS Forecast
$-2.13
2023 EPS Forecast
$-2.36
2024 EPS Forecast
$-2.15
2025 EPS Forecast
$-2.15
2026 EPS Forecast
$-2.15
2027 EPS Forecast
$-2.22
2028 EPS Forecast
$-2.20
2029 EPS Forecast
$-2.18
2030 EPS Forecast
$-2.17